JNK in spinal cord facilitates bone cancer pain in rats through modulation of CXCL1.
10.1007/s11596-016-1547-1
- Author:
Zhong-liang WANG
1
;
Ting-ting DU
2
;
Rui-guang ZHANG
3
Author Information
1. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. zhongliang1989@126.com.
2. Department of Endocrinology, Wuhan Medical and Health Center for Women and Children, Wuhan, 430015, China.
3. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. zrg27@163.com.
- Publication Type:Journal Article
- Keywords:
SP600125;
bone cancer pain;
c-Jun N-terminal kinase;
chemokine (C-X-C motif) ligand 1;
neural-glial interaction
- MeSH:
Animals;
Antibodies, Neutralizing;
immunology;
therapeutic use;
Bone Neoplasms;
complications;
metabolism;
Cancer Pain;
drug therapy;
etiology;
metabolism;
Cell Line, Tumor;
Chemokine CXCL1;
immunology;
metabolism;
Female;
JNK Mitogen-Activated Protein Kinases;
antagonists & inhibitors;
metabolism;
Protein Kinase Inhibitors;
pharmacology;
therapeutic use;
Rats;
Rats, Sprague-Dawley;
Spinal Cord;
metabolism
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2016;36(1):88-94
- CountryChina
- Language:English
-
Abstract:
In patients with advanced cancer, cancer-induced bone pain (CIBP) is a severe and common problem that is difficult to manage and explain. As c-Jun N-terminal kinase (JNK) and chemokine (C-X-C motif) ligand 1 (CXCL1) have been shown to participate in several chronic pain processes, we investigated the role of JNK and CXCL1 in CIBP and the relationship between them. A rat bone cancer pain model was established by intramedullary injection of Walker 256 rat gland mammary carcinoma cells into the left tibia of Sprague-Dawley rats. As a result, intramedullary injection of Walker 256 carcinoma cells induced significant bone destruction and persistent pain. Both phosphorylated JNK1 (pJNK1) and pJNK2 showed time-dependent increases in the ipsilateral spinal cord from day 7 to day 18 after tumor injection. Inhibition of JNK activation by intrathecal administration of SP600125, a selective pJNK inhibitor, attenuated mechanical allodynia and heat hyperalgesia caused by tumor inoculation. Tumor cell inoculation also induced robust CXCL1 upregulation in the ipsilateral spinal cord on day 18 after tumor injection. Inhibition of CXCL1 by intrathecal administration of CXCL1 neutralizing antibody showed a stable analgesic effect. Intrathecal administration of SP600125 reduced CXCL1 increase in the spinal cord, whereas inhibition of CXCL1 in the spinal cord showed no influence on JNK activation. Taken together, these results suggested that JNK activation in spinal cord contributed to the maintenance of CIBP, which may act through modulation of CXCL1. Inhibition of the pJNK/CXCL1 pathway may provide a new choice for treatment of CIBP.
